- Home
- PEN
PEN
Penumbra Inc.
as 10-03-2025 4:00pm EST
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 9.9B | IPO Year: | 2015 |
| Target Price: | $302.93 | AVG Volume (30 days): | 432.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.74 | EPS Growth: | 916.05 |
| 52 Week Low/High: | $189.94 - $310.00 | Next Earning Date: | 10-29-2025 |
| Revenue: | $1,280,152,000 | Revenue Growth: | 12.92% |
| Revenue Growth (this year): | 15.52% | Revenue Growth (next year): | 14.20% |
Stock Insider Trading Activity of Penumbra Inc. (PEN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Elsesser Adam | PEN | CEO | Sep 3 '25 | Sell | $269.64 | 15,800 | $4,260,456.90 | 182,460 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Sep 2 '25 | Sell | $271.19 | 600 | $162,347.05 | 65,083 | |
| Grewal Harpreet | PEN | Director | Sep 2 '25 | Sell | $272.19 | 186 | $50,627.34 | 8,888 | |
| Elsesser Adam | PEN | CEO and President | Aug 20 '25 | Sell | $254.66 | 15,900 | $4,046,952.25 | 182,460 | |
| Bose Arani | PEN | N/A | Aug 13 '25 | Sell | $250.86 | 12,000 | $3,007,775.54 | 558 | |
| Yuen Maggie | PEN | Chief Financial Officer | Aug 13 '25 | Sell | $250.00 | 2,000 | $500,000.00 | 12,943 | |
| Wilder Thomas | PEN | N/A | Aug 12 '25 | Sell | $240.16 | 372 | $89,339.52 | 372 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Aug 11 '25 | Sell | $239.19 | 600 | $143,363.25 | 65,083 |
Latest Penumbra Inc. News
PEN Breaking Stock News: Dive into PEN Ticker-Specific Updates for Smart Investing
PR Newswire
3 months ago
Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025
Zacks
3 months ago
ITGR vs. PEN: Which Stock Is the Better Value Option?
Argus Research
3 months ago
PEN: What does Argus have to say about PEN?
Medical Device Network
3 months ago
Penumbra may gain market share in peripheral embolisation coils with Ruby XL
Zacks
4 months ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
StockStory
4 months ago
The Top 5 Analyst Questions From Penumbra’s Q1 Earnings Call
Simply Wall St.
4 months ago
There's Been No Shortage Of Growth Recently For Penumbra's (NYSE:PEN) Returns On Capital
StockStory
4 months ago
Winners And Losers Of Q1: Penumbra (NYSE:PEN) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
Compare PEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PEN Penumbra Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.